Information Journal Paper
APA:
Copy. (2017). First‑ in‑ human ultrasound molecular imaging with a VEGFR2‑ specific ultrasound molecular contrast agent (BR55) in prostate cancer: A safety and feasibility pilot study. INVESTIGATIVE RADIOLOGY, 52(-), 419-427. SID. https://sid.ir/paper/723211/en
Vancouver:
Copy. First‑ in‑ human ultrasound molecular imaging with a VEGFR2‑ specific ultrasound molecular contrast agent (BR55) in prostate cancer: A safety and feasibility pilot study. INVESTIGATIVE RADIOLOGY[Internet]. 2017;52(-):419-427. Available from: https://sid.ir/paper/723211/en
IEEE:
Copy, “First‑ in‑ human ultrasound molecular imaging with a VEGFR2‑ specific ultrasound molecular contrast agent (BR55) in prostate cancer: A safety and feasibility pilot study,” INVESTIGATIVE RADIOLOGY, vol. 52, no. -, pp. 419–427, 2017, [Online]. Available: https://sid.ir/paper/723211/en